FDA advisory panel rejects widespread Pfizer booster shots, backs boosters for 65 and older, high risk

Coronavirus

WASHINGTON (AP) — An influential federal advisory panel has soundly rejected a plan to offer Pfizer booster shots against COVID-19 to most Americans.

The vote Friday, 16-2, was a blow to the Biden administration’s effort to shore up people’s protection against the virus amid the highly contagious delta variant.

Over several hours of discussion, members of the Food and Drug Administration panel of outside experts voiced frustration that Pfizer had provided little data on safety of extra doses.

The panel also complained that data provided by Israeli researchers about their booster campaign might not be suitable for predicting the U.S. experience.

The panel did endorse booster shots for Americans 65 and older, as well as those who are at a high risk for severe disease.

The decision was made by a committee of outside experts who advise the Food and Drug Administration.

Copyright 2021 Nexstar Media Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.

Trademark and Copyright 2021 The Associated Press. All rights reserved.

Popular

Latest News

More News